Essential Amino Acids 500 mg
100/100
This product looks safe
- No ingredients exceed tolerable upper intake levels
- Limited research evidence available for ingredients
B
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Label Data
6 Capsule(s)
Serving Size
17
Servings
Amino acid/Protein
Product Type
0%
Evidence Coverage
Supplement Facts — Evidence Check
Energy
(1% DV)
Protein
3000 mg
(6% DV)
672 mg
📊 Market median: 17.4mg (161 products)
516 mg
📊 Market median: 500.0mg (159 products)
L-Valine
450 mg
L-Phenylalanine
432 mg
348 mg
📊 Market median: 17.4mg (161 products)
L-Threonine
258 mg
180 mg
📊 Market median: 500.0mg (193 products)
📚 7 studies — no high-quality reviews
72 mg
📊 Market median: 500.0mg (70 products)
L-Cysteine
72 mg
Other Ingredients
L-Leucine
L-Lysine
L-Valine
L-Phenylalanine
L-Isoleucine
L-Threonine
L-Methionine
Gelatin
L-Tryptophan
L-Cysteine
Label Claims — Verification
❓
Nutrient
❓
All Other
All Other (98% of products)
Structure/Function (78% of products)
Nutrient (56% of products)
Target Groups
Children 4 or More Years of Age
Adult (18 - 50 Years)
Product Information
📋 Directions for Use
Adults and children 12 or more years of age: 6 capsules daily or as directed. 6 capsules cover 25% of the recommended daily amount of each essential amino acid recommended by the WHO for a 155 lbs (70 kg) adult.
⚠️ Warnings & Precautions
Store out of reach of young children.
Dietary supplements/food supplements should not be used as a substitute for a varied diet. Do not exceed the stated recommended daily dose.
🧪 Formulation Notes
Made in the USA.
Additional Information
Store in a dry, cool place.
Nominal weight: 60 g % DV = %Daily Values are based on a 2000 calorie diet
Product Details
UPC / SKU
7 640116 922921
DSLD Entry Date
2020-06-24
Product Type
Amino acid/Protein
Form
Capsule
DSLD ID
223131
Data Updated
2026-04-11
Research Evidence
50
Research Sources
47
Avg Quality Score
28
Rct
13
Clinical Trial
5
Guideline
4
Systematic Review
A
Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.
B
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.
B
Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates
B
[Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)].
B
[Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].
B
Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.
B
Baseline-dependent effect of dopamine's precursor L-tyrosine on working memory gating but not updating
C
Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression
Compare Similar Products
L-Tyrosine 500 mg
VitaCeutical Labs
100
Tyrosine
Vitabase
100
L-Tyrosine
Douglas Laboratories
100
L-Tyrosine 500 mg
Douglas Laboratories
100
N-Acetyl-L-Tyrosine 300
LifeLink
100